Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of ...

In the SURPASS-CVOT trial, tirzepatide was similar to dulaglutide for prevention of cardiovascular death, heart attack and stroke at 4 years, researchers reported at the European Association for the ...

Continuing the upmanship battle in expanding the use of GLP-1 drugs beyond diabetes and obesity, Novo Nordisk has released ...

Ozempic® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in ...

The REACH study included data from 58,336 Medicare patients aged 66 years and older with T2D and ASCVD who had initiated either semaglutide or dulaglutide.

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...

Steps for Fitness Success Weight loss is a personal journey, and there’s no single best way to lose weight for men. But ...

A new large-scale study came to the conclusion that weight-loss surgery gives people with type 2 diabetes and obesity a ...

A new drug has shown significant promise as an effective diabetes and weight loss treatment—and can be produced more cheaply.

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

Novo Nordisk (NVO) shares rose 6% premarket on Thursday after a real-world study showed its diabetes drug Ozempic ...